KCT0004817
Recruiting
未知
PET imaging of prostate cancer patients using [F-18]Florastamin for safety and pharmacokinetics study: Phase I clinical trial
FutureChem0 sites10 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- FutureChem
- Enrollment
- 10
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\# Prostate cancer patients
- •1\. Histologically diagnosed prostate cancer patient
- •\- diagnosed with prostate cancer with a biopsy
- •\- patient with an elevated prostate\-specific antigen (PSA) after prostatectomy or radiation treatment
- •\- Clinically confirmed with the progression of prostate cancer
- •2\. Able to provide informed consent and have signed an approved consent form that conforms to institutional guidelines to ensure compliance
- •3\. Men with age \=/\> 19 years
- •4\. ECOG (Eastern Cooperative Oncology Group) Performance scale \=2
- •5\. The life expectancy of greater than or equal to 12 months.
- •6\. Those who satisfy the following conditions in a blood test
Exclusion Criteria
- •1\. A person who is judged to be difficult to perform a clinical trial due to a serious medical condition
- •2\. The person who is determined to have a mental disorder that is difficult to perform PET (Positron Emission Tomography) scan
- •3\. Those participating in other clinical trials at screening and participating in clinical trials should be able to influence the acquisition of \[F\-18]Florastamin PET (Positron Emission Tomography) images from the time of registration until the end of the study, or that may affect the safety assessment following intravenous injection of \[F\-18]Florastamin (For example, if you are participating in another cohort\-based trial that is simply focused on monitoring that you do not receive medicines during screening, you can participate in the current clinical trials.)
- •4\. Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation.
- •5\. Vulnerable subjects (researchers or students who participated in the research, family members, researchers or students of researchers participating in the research)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Evaluation of new PET tracer, [F-18]Florastamin for diagnosing prostate cancerNeoplasmsKCT0003924Korea Cancer Center Hospital6
Active, not recruiting
Phase 1
Imaging of the prostate tumors using PET/CT and PET/MRI with the ligand of the prostatic specific membrane antigene 68Ga-PSMA-11prostatic carcinoma higly suspected or its staging or restagingTherapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]EUCTR2017-004128-32-CZFakultní nemocnice Plzen200
Active, not recruiting
Not Applicable
Diagnostic imaging in prostate cancer (as in tumours with accelerated menbrane turn-over)by F-18 Fluoro-metil-choline PET/CTpatients with prostate cancer istologically provenMedDRA version: 14.1Level: SOCClassification code 10038359Term: Renal and urinary disordersSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 14.1Level: SOCClassification code 10022891Term: InvestigationsSystem Organ Class: 10022891 - InvestigationsTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2008-003337-24-ITCENTRO DI RIFERIMENTO ONCOLOGICO DI BASILICATA
Recruiting
Not Applicable
Diagnostic Performance of PET Imaging for Prostate Specific Membrane Antigen (PSMA)Prostate cancerJPRN-UMIN000037697Osaka University Graduate School of Medicine250
Active, not recruiting
Phase 1
PSMA-PET/CT for prostate cancerEUCTR2017-003461-96-BEGhent University Hospital72